Changes in T-Cell Subsets Identify Responders to FcR-nonbinding Anti-Cd3 mAb (Teplizumab) in Patients With Type 1 Diabetes
European Journal of Immunology - United Kingdom
doi 10.1002/eji.201545708
Full Text
Open PDFAbstract
Available in full text
Date
December 14, 2015
Authors
Publisher
Wiley